Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Technol Cult ; 62(4): 1087-1118, 2021.
Article in English | MEDLINE | ID: mdl-34719514

ABSTRACT

In the late 1970s and early 1980s, NASA's Voyager mission offered the first clear pictures of Jupiter and Saturn. These images show the planets in strikingly brilliant, recognizably engineered, psychedelic colors: technology's palette. The use of color was justified on epistemological grounds; it made visible scientifically compelling features. But color palette also has a history, one that has not been previously considered. This article takes up this history and adds to the literature on the visual culture of science. It establishes that the Jet Propulsion Laboratory's pioneering role in digital image processing, the color conventions adopted for representing Earth, and American counterculture of the 1960s and its attitudes toward technology together created the conditions that allowed for hyperchromatic views of the planets. Technology's palette enhanced the scientific understanding of Jupiter and Saturn, while simultaneously celebrating technologically enhanced vision and the promise of seeing by means of humanmachine collaborations.


Subject(s)
Jupiter , Saturn , Extraterrestrial Environment , Planets , Technology
2.
Pediatr Rheumatol Online J ; 14(1): 54, 2016 Sep 20.
Article in English | MEDLINE | ID: mdl-27646340

ABSTRACT

BACKGROUND: There is a critical shortage of pediatric rheumatologists in the US. Substantial travel to clinics can impose time and monetary burdens on families. The aim of this study was to evaluate the cost of in-person pediatric rheumatology visits for families and determine if telemedicine clinics resulted in time and cost savings. Factors associated with interest in telemedicine were also explored. METHODS: Surveys were offered to parents and guardians of patients in Pediatric Rheumatology follow-up clinics in Kansas City, Missouri, the primary site of in-person care, and at a telemedicine outreach site 160 miles away, in Joplin, Missouri. Survey questions were asked about non-medical, out-of-pocket costs associated with the appointment and interest in a telemedicine clinic. RESULTS: At the primary Kansas City clinic, the median distance traveled one-way was 40 miles [IQR = 18-80]. In the Joplin sample, the median distance traveled to the telemedicine clinic was 60 miles [IQR = 20-85] compared to 175 miles [IQR = 160-200] for the same cohort of patients when seen in Kansas City (p < 0.001). When the Joplin cohort was seen via telemedicine they missed less time from work and school (p = 0.028, p = 0.003, respectively) and a smaller percentage spent money on food compared to when they had traveled to Kansas City (p < 0.001). There was no statistical difference between the Joplin cohort when they had traveled to Kansas City and the Kansas City cohort in terms of miles driven to clinic, time missed from work and school, and percentage of subjects who spent money on food. CONCLUSIONS: Traditional in-person visits can result in a financial toll on families, which can be ameliorated by the use of telemedicine. Telemedicine leveled the economic burden of clinic visits so that when the Joplin cohort was seen via telemedicine, they experienced costs similar to the Kansas City cohort.


Subject(s)
Cost Savings/methods , Cost of Illness , Financing, Personal/economics , Rheumatic Diseases , Telemedicine , Transportation of Patients/economics , Ambulatory Care/economics , Child , Cross-Sectional Studies , Female , Health Services Accessibility/economics , Humans , Male , Pediatrics/methods , Pediatrics/organization & administration , Rheumatic Diseases/economics , Rheumatic Diseases/therapy , Rheumatology/methods , Rheumatology/organization & administration , Telemedicine/economics , Telemedicine/methods , Telemedicine/organization & administration , United States
3.
Best Pract Res Clin Rheumatol ; 28(2): 293-313, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24974064

ABSTRACT

The treatment of juvenile idiopathic arthritis (JIA) has substantially evolved over the past two decades. Research has been conducted and is ongoing on how therapies can best be utilized either as monotherapy or in combination for enhanced efficacy. The introduction of biologic therapies that selectively target specific cytokines has changed the acceptable clinical course of childhood arthritis. In addition to the development and utilization of new therapeutic agents, the pediatric rheumatology community has made vital progress toward defining disease activity, developing validated outcome measures, and establishing collaborative networks to assess both clinical outcomes and the long-term side effects related to therapeutics for juvenile arthritis. In this chapter, we will discuss the therapeutic evolution in JIA over the past two decades. Although the largest strides have been made with biologic agents, and these newer drugs have more rigorous data to support their use, select commonly used non-biologic therapies are included, with the discussion focused on more recent updated literature.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/therapy , Biological Therapy , Arthritis, Juvenile/drug therapy , Biological Factors/therapeutic use , Humans , Immunologic Factors/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors
4.
Pediatrics ; 133(3): 493-9, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24515516

ABSTRACT

BACKGROUND AND OBJECTIVE: Dexamethasone has been proposed as an equivalent therapy to prednisone/prednisolone for acute asthma exacerbations in pediatric patients. Although multiple small trials exist, clear consensus data are lacking. This systematic review and meta-analysis aimed to determine whether intramuscular or oral dexamethasone is equivalent or superior to a 5-day course of oral prednisone or prednisolone. The primary outcome of interest was return visits or hospital readmissions. METHODS: A search of PubMed (Medline) through October 19, 2013, by using the keywords dexamethasone or decadron and asthma or status asthmaticus identified potential studies. Six randomized controlled trials in the emergency department of children ≤18 years of age comparing dexamethasone with prednisone/prednisolone for the treatment of acute asthma exacerbations were included. Data were abstracted by 4 authors and verified by a second author. Two reviewers evaluated study quality independently and interrater agreement was assessed. RESULTS: There was no difference in relative risk (RR) of relapse between the 2 groups at any time point (5 days RR 0.90, 95% confidence interval [CI] 0.46-1.78, Q = 1.86, df = 3, I2 = 0.0%, 10-14 days RR 1.14, 95% CI 0.77-1.67, Q = 0.84, df = 2, I2 = 0.0%, or 30 days RR 1.20, 95% CI 0.03-56.93). Patients who received dexamethasone were less likely to experience vomiting in either the emergency department (RR 0.29, 95% CI 0.12-0.69, Q = 3.78, df = 3, I2 = 20.7%) or at home (RR 0.32, 95% CI 0.14-0.74, Q = 2.09, df = 2, I2 = 4.2%). CONCLUSIONS: Practitioners should consider single or 2-dose regimens of dexamethasone as a viable alternative to a 5-day course of prednisone/prednisolone.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Asthma/drug therapy , Dexamethasone/therapeutic use , Acute Disease , Asthma/diagnosis , Asthma/epidemiology , Child , Clinical Trials as Topic/methods , Humans
5.
Arthritis Care Res (Hoboken) ; 66(3): 404-10, 2014 Mar.
Article in English | MEDLINE | ID: mdl-23983017

ABSTRACT

OBJECTIVE: To investigate aspects of juvenile dermatomyositis (DM), including disease characteristics and treatment, through a national multicenter registry. METHODS: Subjects meeting the modified Bohan and Peter criteria for definite juvenile DM were analyzed from the cross-sectional Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry between 2010 and 2012 from 55 US pediatric rheumatology centers. Demographics, disease characteristics, diagnostic assessments, and medication exposure data were collected at enrollment. RESULTS: A total of 384 subjects met the criteria for analysis. At enrollment, the median Childhood Myositis Assessment Scale score was 51 (interquartile range [IQR] 46-52), the median Childhood Health Assessment Questionnaire score was 0 (IQR 0-0.5), and the median physician and subject global assessment scores were 1 (IQR 0-2) and 1 (IQR 0-3), respectively, out of a maximum of 10. Of the diagnostic assessments, magnetic resonance imaging was more likely than electromyography or muscle biopsy to show abnormalities. A total of 329 subjects had ≥2 diagnostic studies performed, and >34% of these subjects reported ≥1 negative study. Ninety-five percent had been treated with corticosteroids and 92% with methotrexate, suggesting that these medications were almost universally prescribed for juvenile DM in the US. CONCLUSION: In 2 years, the ongoing CARRA Registry has collected clinical data on 384 children with juvenile DM and has the potential to become one of the largest juvenile DM cohorts in the world. More research is needed about prognostic factors in juvenile DM, and differences in therapy based on manifestations of disease need to be explored by practitioners. This registry provides the infrastructure needed to advance clinical and translational research and represents a major step toward improving outcomes of children with juvenile DM.


Subject(s)
Dermatomyositis/epidemiology , Registries , Adolescent , Child , Cross-Sectional Studies , Dermatomyositis/diagnosis , Dermatomyositis/drug therapy , Female , Humans , Male , Rheumatology/organization & administration
6.
Curr Allergy Asthma Rep ; 13(4): 337-46, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23605168

ABSTRACT

Juvenile idiopathic arthritis (JIA) is one of the most common chronic diseases of childhood. Although the pathophysiology behind this disease is poorly understood, there are effective treatments for JIA based on the subtype of disease. Treatment options include non-steroidal anti-inflammatory drugs, intra-articular glucocorticoid injections, and traditional disease modifying anti-rheumatic drugs such as methotrexate. In the past decade, the use of biologic therapy in JIA, including tumor necrosis factor inhibitors, interleukin-1 inhibitors, and interleukin-6 inhibitors, has dramatically increased with promising outcomes.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Biological Therapy , Glucocorticoids/therapeutic use , Humans , Immunologic Factors/therapeutic use , Interleukin-1/therapeutic use , Interleukin-6/therapeutic use , Methotrexate/therapeutic use , Tumor Necrosis Factor-alpha/therapeutic use
7.
Pediatr Rheumatol Online J ; 10(1): 30, 2012 Aug 29.
Article in English | MEDLINE | ID: mdl-22931129

ABSTRACT

Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility that patients with a tendency towards MAS have an increased risk of developing cytopenias when treated with tocilizumab.

SELECTION OF CITATIONS
SEARCH DETAIL
...